Due Diligence Summit

Transcription

1 The ONLY life science event focused on the needs of cross-functional due diligence professionals 4th Due Diligence Summit for Life Sciences Benchmark your due diligence practices for evaluating business development opportunities, strategic partnerships and external sources of innovation Speakers May 18-19, 2017 Hyatt Regency Boston Boston, MA Luba Greenwood Vice, Global Business Development and Mergers and Acquisitions F. HOFFMAN-LA ROCHE Catherine Baillis Vice, Head of Business Development Operations, Business Development and Licensing SANOFI Mike Myers Senior Director, Lilly Research Labs Due Diligence KEY TAKEAWAYS: Michael B. Kennedy II Vice - DataSite, MERRILL Examine buy-side and sell-side perspectives on evaluating licensing and acquisition opportunities Allan Weber CEO ESSENTIAL PHARMACEUTICAL Navigate the differences between conducting due diligence for digital health versus molecule-driven targets Explore examples from mid-sized and large companies on developing a formal due diligence function Matthew Handel RECENSA THERAPEUTICS Edward Mahony Executive Vice, Due Diligence and Integration PURDUE PHARMA Sponsors: Gain valuable insight through case studies and an interactive learning activity with industry leaders Hear from aitional featured speakers representing venture capitalist firms; biotechs; and organizations such as Novartis, Merck, Teva and PATH! Curt H. Labelle, M.D., MBA GLOBAL HEALTH INVESTMENT FUND

2 4th Due Diligence Summit for Life Sciences DEAR COLLEAGUE, Scientific innovations, the new administration, and pricing and reimbursement challenges have led to an uncertain healthcare landscape and catalyzed major transformations in the life science industry saw 22 new drug approvals, down from 45 in 2015, which spotlights the risky nature of R&D investments and organic development. This increasingly competitive marketplace, coupled with declining revenues, has prompted companies to reevaluate their portfolio strategies and divest products to focus on specific therapeutic areas where they hold the strongest market position. In order to prepare for patent expirations and bolster product portfolios, organizations are increasingly looking to external targets and sources of innovation to invest in. This strategic approach requires an organization to have a robust due diligence process in place to evaluate acquisition, licensing and partnership opportunities. Join your peers at the 4th Due Diligence Summit for Life Sciences for two days of case studies, panel discussions and informative sessions on the most pressing issues in the due diligence arena. Our experienced faculty will outline the critical information required to make informed decisions regarding digital health technologies, examine methodologies to determine the potential of an investment in compressed time frames and understand strategic approaches to optimizing product portfolios to meet growth objectives. Don t miss this opportunity to join our growing life science due diligence community! I look forward to welcoming you to Boston this summer. WHO SHOULD ATTEND This conference is designed for representatives from pharmaceutical, medical device and biotechnology companies with responsibilities in the following areas: Due Diligence Business Development Strategic Alliance/Alliance Management Mergers and Acquisitions Licensing Intellectual Property and Patent Counsel Search and Evaluation Portfolio Management Scientific Assessment General Counsel/Corporate Counsel Legal and Regulatory Compliance Regulatory Affairs Research and Development Clinical Medicine Clinical Operations Life Cycle Management This conference is also of interest to: Investment Banks Private Equity Firms Venture Capitalists Data Room Providers Due Diligence Consultants Law Firms Clinical Affairs and CRO Partners Regulatory Affairs and Compliance Partners Sincerely, Zohaib Sheikh Zohaib Sheikh Senior Conference Director ExL Events, a Division of Questex, LLC I work in due diligence and this was right up my alley. Content was spot on with the right people invited to present. Director, Commercial Assessment, SHIRE VENUE INFORMATION Hyatt Regency Boston 1 Ave de Lafayette Boston, MA To make reservations, please call toll free or and request the negotiated rate for ExL s 4th Due Diligence Summit. You may also make reservations online at The group rate is available until April 26, Please book your room early, as rooms available at this rate are limited. *ExL Events is not affiliated with Exhibition Housing Management (EHM)/Exhibitors Housing Services (EHS) or any third-party booking agencies, housing bureaus or travel companies. ExL Events is affiliated with event company Questex, LLC. In the event that an outside party contacts you for any type of hotel or travel arrangements, please disregard these solicitations and kindly us at info@exlevents.com. ExL has not authorized these companies to contact you and we do not verify the legitimacy of the services or rates offered. Please book your guest rooms through ExL s reserved guest room block using the details provided. SPONSORSHIP AND EXHIBITION OPPORTUNITIES Do you want to spread the word about your organization s solutions and services to potential clients who will be attending this event? Take advantage of the opportunity to exhibit, underwrite an educational session, host a networking event or distribute promotional items to attendees. ExL Events will work closely with you to customize a package that will suit all of your needs.

3 AGENDA Thursday, May 18, 2017 // Day One 8:00 Registration and Continental Breakfast 8:45 Co-Chairpersons Opening Remarks Michael B. Kennedy II, Vice - DataSite, MERRILL 9:00 Design, Develop and Launch a Due Diligence Function Create a process map, checklists and report templates Form an internal team guided by external experts Train the internal team and evaluate project performance Review the 18-month journey of creating this new function Edward Mahony, Executive Vice, Due Diligence and Integration, PURDUE PHARMA 9:45 Center of Excellence: An Organizational Model for Driving Continuous Improvement in Due Diligence Practice Examine the internal causes and motivations for developing a center of excellence Understand the difficulties faced by the organization on a functional, regional and global level Explore the process by which Novartis created a function that aligns strategic objectives and creates awareness across the company Courtney Horvath, Ph.D., DABT, Preclinical Safety Global Coordinator, Novartis Institutes for Biomedical Research, NOVARTIS 10:30 Networking Break 11:00 Seven Critical M&A Transaction Mistakes to Avoid Identify the mistakes that can derail successful M&A deals and learn how to avoid common pitfalls Uncover synergy savings that can prevent deal fatigue and postmerger business problems Develop an effective management and communication strategy that articulates individual expectations and the benefits of the integrated organization Evaluate the advantages of controlled access during the M&A transaction process Michael B. Kennedy II, Vice - DataSite, MERRILL 11:45 Case Study: Digital Health s Role in Reshaping the Diligence Landscape for Biotech and Life Sciences Outline the unique approach required to conduct due diligence on digital health targets Case Study Acknowledge the importance of understanding the value proposition and strategic fit Highlight the challenges and advantages of an acquisition, as well as the integration difficulties Recognize the necessary expertise required for the ideal team and how this can differ from other diligence teams Luba Greenwood, Vice, Global Business Development and Mergers and Acquisitions, F. HOFFMAN-LA ROCHE 1:30 Explore the VC Perspective on Due Diligence and Valuations Gain an overview of different valuation models and how VCs and financial institutions evaluate transactions Assess the strengths of VCs and how to leverage them as partners during the due diligence process Review case studies from past deals Curt H. Labelle, M.D., MBA,, GLOBAL HEALTH INVESTMENT FUND 2:15 Case Study: Create the Value Proposition of a Specialty Product in a Niche Space Hear about the out-licensing of a very specialized product in a highly divergent market of a few big pharma players and many Case Study biopharma companies Examine how the story developed to show the value of a highly specialized product that was well-positioned in the market, in an effort to entice buyers Recognize the complicating factors such as patent protection that came into play and the thought process that led to the decision of out-licensing Allan Weber, CEO, ESSENTIAL PHARMACEUTICAL 3:00 Panel: Effectively Prepare Your Company or Product to Attract Investors for Partnering or Acquisition Analyze how biotechs and mid-sized to large pharmaceutical companies differ in their approaches to engaging on a Panel collaboration or acquisition Identify the key areas for due diligence before an investment or IPO event and considerations for an exit Highlight the important questions that need to be asked that can help prevent a deal from backfiring Curt H. Labelle, M.D., MBA,, GLOBAL HEALTH INVESTMENT FUND Matthew Handel,, RECENSA THERAPEUTICS Marc Schwabish, US Head, Pharmaceutical Business Development and Licensing, BAYER 3:45 Networking Break 4:15 How Small Companies Should Conduct Due Diligence on Their Large Company Partners Discuss what information a small company should investigate about larger companies Outline how can you gather this information Understand how to set up a successful integration using this process Matthew Handel,, RECENSA THERAPEUTICS 5:00 Interactive Learning Discussion Discuss due diligence challenges and successes in an informal setting Share best practices and strategies as a group for problems suggested by your peers Explore innovative approaches to due diligence as conducted by industry leaders 12:30 Luncheon 5:45 Day One Concludes

4 AGENDA Friday, May 19, 2017 // Day Two 8:00 Continental Breakfast 12:30 Luncheon 8:45 Co-Chairpersons Recap of Day One Michael B. Kennedy II, Vice - DataSite, MERRILL 9:00 Methodologies for Risk Assessment in Due Diligence Highlight why risk management is a key part of due diligence Develop a risk assessment framework: Notions of criticality, severity and control Establish risk mitigation plans and solutions for making deals Catherine Baillis, Vice, Head of Business Development Operations, Business Development and Licensing, SANOFI 9:45 Assess a Target Company s Existing Commercial and Research Relationships Identify existing and future commercial and IP risks early in the deal Evaluate techniques for minimizing risk at all stages of deal discussions and due diligence Highlight the importance of post-acquisition diligence John Dougherty, Partner, FROMMER LAWRENCE AND HAUG LLP 10:30 Networking Break 11:00 Best Practices for Due Diligence on Research Collaborations and Partnerships Conduct organizational and capabilities-focused due diligence Gain strategic and operational alignment with partners Structure collaborations that maximize partner strengths Diane Harvey, Ph.D., Senior Director, Search and Evaluation, TEVA 11:45 Advantages and Challenges of Academic-Industry Partnerships Examine some of the different types of academic-industry collaborations over the years, such as the funding of basic research and potential licensing opportunities Highlight some recent deals and discuss what works well for these partnerships Understand what challenges need to be aressed when these two types of institutions enter into an agreement Lizabeth Leveille, Executive Director, BD&L Transactions, MERCK 1:30 The Integration of an Acquired Company: How the Nature of a Deal Will Have a Dramatic Impact on the Handling of Employees Review the fundamental differences to employees brought about by a stock deal versus an asset deal Gain an understanding of the specific components of compensation and employee benefits and their impact on integration Learn the pre-closing HR activities that will enhance a successful integration of the business Joseph Bulvid, Former Vice, Global Benefits, Planning and Mergers and Acquisitions, JOHNSON & JOHNSON; Adjunct Professor, Leadership and Human Capital Management Department, NYU 2:15 Explore the Reality of Due Diligence in the Context of Global Health Product Development Analyze the complex health needs affecting populations in the developing world and how they can be met through innovative strategies Evaluate the significant financial opportunities presented by global health product development for investors and companies Understand how potential investors and partners should assess these opportunities David Shoultz, Ph.D., M.S., MBA, Global Program Leader, Drug Development, PATH 3:00 Panel: Uncertainty, Challenges and Opportunities in the Trump Era Hear perspectives from leaders at pharmaceutical, venture capital and global health companies Panel Explore how pricing practices have drawn public and government scrutiny and how this close examination has impacted deal structuring Examine and discuss the new administration and evolving policies that affect the life sciences industry in the US David Shoultz, Ph.D., M.S., MBA, Global Program Leader, Drug Development, PATH Robert Bagdorf, M.D., MBA, Vice, Worldwide Business Development, PFIZER 3:45 Co-Chairpersons Closing Remarks Michael B. Kennedy II, Vice - DataSite, MERRILL 4:00 Conference Concludes This conference improved my understanding of other aspects of diligence and helped me learn how other companies manage their processes. Director, CMC Business Development, MERCK Simple yet powerful guidance on the questions that need to be considered. Project Manager, Strategic Transactions, Worldwide Business Development, PFIZER

5 Registration Fees for Attending ExL s 4th Due Diligence Summit for Life Sciences: EARLY BIRD PRICING Register by March 31, 2017 Conference $1,895 STANDARD PRICING Register After March 31, 2017 Conference $2,095 ONSITE PRICING Conference $2,195 GROUP DISCOUNT PROGRAM Offers may not be combined. Early bird rates do not apply. To find out more on how you can take advantage of these group discounts, please call SAVE 25% SAVE 15% MEDIA PARTNERS PER PERSON WHEN REGISTERING FOUR For every three simultaneous registrations from your company, you will receive a fourth complimentary registration to the program (must register four at one time). This is a savings of 25% per person. PER PERSON WHEN REGISTERING THREE Can only send three? You can still save 15% off of every registration. TERMS AND CONDITIONS: By registering for an ExL Events ( ExL ) event, you agree to the following set of terms and conditions listed below: REGISTRATION FEE: The fee includes the conference all program materials and designated continental breakfasts lunches and refreshments. PAYMENT: Make checks payable to ExL Events and write C884 on your check. You may also use Visa, MasterCard, Discover or American Express. Payments must be received in full by the conference date. Any discount applied cannot be combined with any other offer and must be paid in full at the time of order. Parties must be employed by the same organization and register simultaneously to realize group discount pricing options. **Please Note: There will be an administrative charge of $300 to substitute, exchange and/or replace attendance badges with a colleague within five business days of any ExL conference.** CANCELLATION AND REFUND POLICY: If you cancel your registration for an upcoming ExL event, the following policies apply, derived from the Start Date of the event: Four weeks or more: A full refund (minus a $295 processing fee) or a voucher to another ExL event valid for 12 months from the voucher issue date. Less than four weeks: A voucher to another ExL event valid for 12 months from the voucher issue date. Five days or less: A voucher (minus a $395 processing and documentation fee) to another ExL event valid for 12 months from the voucher issue date. CREDIT VOUCHERS: Credit vouchers are valid for 12 months from date of issue. Credit vouchers are valid toward one (1) ExL event of equal or lesser value. If the full amount of said voucher is not used at time of registration, any remaining balance is not applicable now or in the future. Once a credit voucher has been applied toward a future event, changes cannot be made. In the event of cancellation on the attendees behalf, the credit voucher will no longer be valid. ExL Events does not and is not obligated to provide a credit voucher to registered attendee(s) who do not attend the event they registered for unless written notice of intent to cancel is received and confirmed prior to the commencement of the event. SUBSTITUTION CHARGES: There will be an administrative charge of $300 to substitute, exchange and/or replace attendee badges with a colleague occurring within five business days of the conference. ExL Events reserves the right to cancel any conference it deems necessary and will not be responsible for airfare hotel or any other expenses incurred by registrants. ExL Events liability is limited to the conference registration fee in the event of a cancellation and does not include changes in program date content speakers and/ or venue. *The opinions of ExL s conference speakers do not necessarily reflect those of the companies they represent, nor ExL Events. Please Note: Speakers and agenda are subject to change without notice. In the event of a speaker cancellation, significant effort to find a suitable replacement will be made. The content in ExL slide presentations, including news, data, advertisements and other information, is provided by ExL s designated speakers and is designed for informational purposes for its attendees. It is NOT INTENDED for purposes of copywriting or redistribution to other outlets without the express written permission of ExL s designated speaking parties. Neither ExL nor its content providers and/ or speakers and attendees shall be liable for any errors, inaccuracies or delays in content, or for any actions taken in reliance thereon. EXL EVENTS EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESSED OR IMPLIED, AS TO THE ACCURACY OF ANY CONTENT PROVIDED, OR AS TO THE FITNESS OF THE INFORMATION FOR ANY PURPOSE. Although ExL makes reasonable efforts to obtain reliable content from third parties, ExL does not guarantee the accuracy of, or endorse the views or opinions given by any third-party content provider. ExL presentations may point to other websites that may be of interest to you, however ExL does not endorse or take responsibility for the content on such other sites.

6 Method of Payment: Check Make checks payable to PMA Conference Management. Card Type: MasterCard Visa Discover AMEX Card Number: Name on Card: Exp. Date: CVV: Signature: Please contact me: I'm interested in marketing opportunities at this event. I wish to receive updates on ExL Events upcoming events. Conference Code: C884 Yes! Register me for the conference. Name: Title: Company: Dept.: Aress: City: State: Zip: Phone: Fax: 4th The ONLY life science event focused on the needs of cross-functional due diligence professionals Due Diligence Summit for Life Sciences Benchmark your due diligence practices for evaluating business development opportunities, strategic partnerships and external sources of innovation Speakers May 18-19, 2017 Hyatt Regency Boston Boston, MA Mike Myers Senior Director, Lilly Research Labs - Due Diligence Michael B. Kennedy II Vice - DataSite, MERRILL Luba Greenwood Vice, Global Business Development and Mergers and Acquisitions F. HOFFMAN-LA ROCHE Catherine Baillis Vice, Head of Business Development Operations, Business Development and Licensing SANOFI Allan Weber CEO ESSENTIAL PHARMACEUTICAL Matthew Handel RECENSA THERAPEUTICS Edward Mahony Executive Vice, Due Diligence and Integration PURDUE PHARMA Curt H. Labelle, M.D., MBA GLOBAL HEALTH INVESTMENT FUND